Edition:
United Kingdom

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

8.80USD
17 Aug 2018
Change (% chg)

$-0.47 (-5.07%)
Prev Close
$9.27
Open
$9.20
Day's High
$9.43
Day's Low
$8.54
Volume
344,432
Avg. Vol
82,459
52-wk High
$22.92
52-wk Low
$5.22

Latest Key Developments (Source: Significant Developments)

Idera Pharmaceuticals Q2 Loss Per Share $0.59
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Idera Pharmaceuticals Inc ::IDERA PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.59.Q2 EARNINGS PER SHARE VIEW $-0.82 -- THOMSON REUTERS I/B/E/S.  Full Article

Idera Pharmaceuticals Announces One-For-Eight Reverse Stock Split
Friday, 27 Jul 2018 

July 27 (Reuters) - Idera Pharmaceuticals Inc ::IDERA PHARMACEUTICALS ANNOUNCES ONE-FOR-EIGHT REVERSE STOCK SPLIT.IDERA PHARMACEUTICALS - BOARD APPROVED A ONE-FOR-EIGHT REVERSE STOCK SPLIT OF COMMON STOCK THAT WILL BE EFFECTIVE AT 5:00 PM ET JULY 27.  Full Article

Biocryst Pharmaceuticals Says Merger Agreement Terminated With Idera Pharmaceuticals
Tuesday, 10 Jul 2018 

July 11 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS ANNOUNCES TERMINATION OF MERGER AGREEMENT WITH IDERA PHARMACEUTICALS.BIOCRYST PHARMACEUTICALS INC - TERMINATED PREVIOUSLY ANNOUNCED MERGER AGREEMENT WITH IDERA PHARMACEUTICALS.BIOCRYST PHARMACEUTICALS INC - IN ACCORDANCE WITH TERMS OF MERGER AGREEMENT, BIOCRYST WILL REIMBURSE IDERA FOR TRANSACTION-RELATED EXPENSES OF $6 MILLION.BIOCRYST - TERMINATED MERGER AGREEMENT AFTER BIOCRYST STOCKHOLDERS' FAILURE TO APPROVE ADOPTION OF MERGER AGREEMENT AT SPECIAL MEETING.  Full Article

Great Point Partners Says Delivered Letter To Biocryst Pharma
Wednesday, 20 Jun 2018 

June 20 (Reuters) - BioCryst Pharmaceuticals Inc ::GREAT POINT PARTNERS SAYS DELIVERED LETTER TO BIOCRYST PHARMACEUTICALS REAFFIRMING ITS OBJECTIONS TO PROPOSED MERGER OF BIOCRYST & IDERA PHARMACEUTICALS.  Full Article

Idera Pharmaceuticals Reports Results From Phase 2 Trial Of Imo-8400 In Dermatomyositis
Tuesday, 12 Jun 2018 

June 12 (Reuters) - Idera Pharmaceuticals Inc ::IDERA PHARMACEUTICALS REPORTS RESULTS FROM PHASE 2 TRIAL OF IMO-8400 IN DERMATOMYOSITIS.IDERA PHARMACEUTICALS INC - TRIAL DID NOT MEET ITS PRIMARY ENDPOINT.IDERA PHARMACEUTICALS INC - ANNOUNCED TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF IMO-8400 IN ADULT PATIENTS WITH DERMATOMYOSITIS.  Full Article

Biocryst Urges Stockholders To Vote "For" Merger Transaction With Idera
Tuesday, 5 Jun 2018 

June 5 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS INC SAYS URGE STOCKHOLDERS TO VOTE "FOR" MERGER TRANSACTION WITH IDERA PHARMACEUTICALS.  Full Article

Idera Pharmaceuticals Enters Into A Clinical Trial Collaboration And Supply Agreement With Bristol-Myers Squibb
Thursday, 24 May 2018 

May 24 (Reuters) - Bristol-Myers Squibb Co ::IDERA PHARMACEUTICALS SAYS EFFECTIVE MAY 18, 2018 ENTERED INTO A CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH BRISTOL-MYERS SQUIBB.IDERA PHARMACEUTICALS - DEAL TO CLINICALLY EVALUATE COMBINATION OF CO'S TLR-9 AGONIST IMO-2125 WITH BMS'S THERAPY YERVOY.IDERA PHARMACEUTICALS INC - BMS GRANTED CO NON-EXCLUSIVE, NON-TRANSFERRABLE, ROYALTY-FREE LICENSE UNDER INTELLECTUAL PROPERTY TO USE YERVOY IN TRIAL.IDERA PHARMACEUTICALS - WILL SPONSOR, FUND, CONDUCT CO'S OPEN-LABEL, MULTI-CENTER PHASE 3 CLINICAL TRIAL OF TILSOTOLIMOD IN COMBINATION WITH YERVOY.IDERA PHARMACEUTICALS INC - UPON TERMINATION OF DEAL, LICENSES GRANTED TO CO TO USE YERVOY(REG) IN TRIAL WILL TERMINATE.  Full Article

Idera Pharmaceuticals Reports Q1 Loss Per Share $0.10
Wednesday, 9 May 2018 

May 9 (Reuters) - Idera Pharmaceuticals Inc ::IDERA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.10.Q1 EARNINGS PER SHARE VIEW $-0.09 -- THOMSON REUTERS I/B/E/S.AS OF MARCH 31, 2018, CASH AND CASH EQUIVALENTS TOTALED $107.5 MILLION COMPARED TO $112.6 MILLION AS OF DECEMBER 31, 2017.SEES EXISTING CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND OPERATIONS INTO Q3 OF 2019.  Full Article

Idera Pharmaceuticals Enters Into A Clinical Development Support Agreement With Pillar Partners Foundation
Monday, 16 Apr 2018 

April 16 (Reuters) - Idera Pharmaceuticals Inc ::IDERA PHARMACEUTICALS ENTERS INTO A CLINICAL DEVELOPMENT SUPPORT AGREEMENT WITH PILLAR PARTNERS FOUNDATION TO EXPAND THE CLINICAL RESEARCH ON IMO-2125 BEYOND PD-1 REFRACTORY MELANOMA.IDERA PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, PILLAR PARTNERS TO PROVIDE DIRECT FUNDING TO EXPAND CLINICAL RESEARCH OF IMO-2125.  Full Article

Biocryst Pharma And Idera Pharma Sign Merger Agreement To Form New Company
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Biocryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS AND IDERA PHARMACEUTICALS ANNOUNCE MERGER TO COMBINE CAPABILITIES TO SERVE MORE PATIENTS WITH RARE DISEASES.IDERA PHARMACEUTICALS INC - ‍MERGER AGREEMENT HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES​.IDERA PHARMACEUTICALS INC - ROBERT INGRAM TO BE CHAIRMAN OF BOARD, VINCENT MILANO TO BE CEO OF COMBINED COMPANY.IDERA PHARMACEUTICALS - UNDER TERMS OF MERGER AGREEMENT, EACH SHARE OF BIOCRYST COMMON STOCK WILL BE EXCHANGED FOR 0.50 SHARES OF NEW COMPANY STOCK.IDERA PHARMACEUTICALS - UNDER TERMS OF MERGER AGREEMENT, EACH SHARE OF IDERA COMMON STOCK WILL BE EXCHANGED FOR 0.20 SHARES OF NEW COMPANY STOCK.IDERA PHARMACEUTICALS - ‍SIGNIFICANT STOCKHOLDER OF CO, BIOCRYST AGREED TO ENTER VOTING AND SUPPORT AGREEMENT AND HAS AGREED TO VOTE IN FAVOR OF DEAL​.IDERA PHARMACEUTICALS INC - AFTER DEAL BIOCRYST STOCKHOLDERS WILL OWN 51.6 PERCENT OF STOCK OF COMBINED COMPANY, CO'S STOCKHOLDERS TO OWN 48.4 PERCENT.IDERA PHARMACEUTICALS - COMBINED COMPANY, WHICH WILL BE RENAMED POST-CLOSING, WILL BE HEADQUARTERED AT CURRENT IDERA HEADQUARTERS.IDERA PHARMACEUTICALS INC - STOCK ISSUANCE IN MERGER IS EXPECTED TO BE TAX-FREE TO STOCKHOLDERS.  Full Article

BRIEF-Idera Pharmaceuticals Reports Q1 Loss Per Share $0.10

* IDERA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE